Biograph.

What Biograph actually is

The clinical home of Medicine 3.0, the framework Peter Attia has been articulating across his book and podcast since 2023. Biograph is the institutional version of that work — a membership clinic, opened publicly in early 2025, that runs the diagnostic spread Attia argues is the actual minimum-credible workup for the patient who wants their next forty years to look like the previous forty.

The model is annual: a multi-day intake, structured follow-up across the year, and a re-baseline twelve months later. The depth of the workup is comparable to YEARS at the upper tier; the model differs in being explicitly longitudinal rather than punctual.

What you actually get

The Core membership ($17,500/year) buys 20+ assessments. Whole-body MRI on a 3T magnet. DEXA composition. CPET-grade VO₂ max with lactate threshold. Genetic testing. The hormonal and metabolic depth is significant; the cardiovascular workup includes a coronary calcium score by default.

Black membership ($32,500/year) extends to 30+ assessments. The major additions are CT coronary angiography (a step beyond calcium scoring), multi-cancer early detection (Galleri-class liquid biopsy), and multi-modal brain health imaging including specialist neurocognitive review. The price step is real; the diagnostic step is also real.

Both tiers include the work that most clinics fail at: the quarterly clinician contact, the protocol revision, the specialist referrals when the data warrants them.

On the conflict-of-interest question

Biograph is one of the few American clinics in the upper tier we believe deserves credit on this axis. The membership is the revenue line. There is no peptide protocol upsell, no NAD+ infusion suite, no hormone replacement programme administered down the hall from the diagnostic that found the abnormality. Specialists, when needed, are referred outside the membership.

This is not pure independence — the clinic will still want you to renew next year — but the financial geometry is meaningfully different from a clinic that profits from each protocol it adds.

Where it falls short

Two structural caveats.

Multi-cancer early detection and full-body MRI both carry a meaningful false-positive cost. Biograph’s clinical team handles the resulting workups well, in our reading, but the reader should know that ‘urgent finding’ counts the way they do — in published data on Galleri-class assays, the positive predictive value sits around 38–43%, meaning a meaningful share of positives turn out to be benign on workup. The downstream MRI-driven cost and anxiety are real.

The membership is currently US-only. International readers, particularly in Europe, have closer-to-home options at YEARS or Hirslanden.

The verdict

The closest American answer to YEARS in this directory. Same diagnostic-first instinct, longer-running membership structure, the explicit Medicine 3.0 thesis to organise the work around. For the US-based reader prepared to commit to an annual cadence, Biograph is — currently — the highest-scoring choice we have.

A clinic that bills annually for the longitudinal work is closer to the right model than a clinic that bills protocol-by-protocol for the year of work that follows.